is one of the agents publicly offered for development by the Review Committee on Unapproved Drugs and Indications with High Medical Needs.
Tablets is utilized to relieve moderate to severe pain in patients where the usage of an opioid is appropriate.
Conclusion and Clinical Relevance--Results indicated hydromorphone hydrochloride
had high bioavailability and rapid elimination after IM administration, with a short terminal half-life, rapid plasma clearance, and large volume of distribution in American kestrels.
This FDA approval enables the company to start the commercial manufacturing and packaging of Hydromorphone Hydrochloride
She has not been started on PCA yet, and the house staff has just written an order for hydromorphone hydrochloride
EXALGO is contraindicated in opioid non-tolerant patients, in management of mild pain or pain not expected to persist, in patients with compromised respiratory function or in patients with narrowed or obstructed gastrointestinal tract or with known hypersensitivity to any components including hydromorphone hydrochloride
Dalteparin, darbepoetin, dasatinib, dexamethasone + neomycin sulphate + polymyxin B sulfate, epoetin beta, epoetin theta, epoetin zeta, erlotinib, estradiol + cyproterone, etoricoxib, everolimus, follitropin beta, formoterol + beclomethasone, fusidic + betamethasone, fusidic + hydrocortisone , goserelin, hydromorphone hydrochloride
, ketorolac, levothyroxine + liothyronine, Linezolid, nadroparin, paliperidone palmitate, pazopanib, pegfilgrastim, piribedil, progesterone, prothipendyl, Reviparin, risperidone, sildenafil, sumatriptan, tinzaparin, tobramycin, tobramycin + dexamethasone, voriconazole.
The company launched: dipyridamole tablets, USP; quetiapine fumarate tablets; tinidazole tablets; hydromorphone hydrochloride
oral solution, USP; nevirapine oral suspension; montelukast sodium tablets; montelukast sodium chewable tablets; oxcarbazepine oral suspension; irbesartan and hydrochlorothiazide tablets, USP; and irebesartan tablets, USE
15 December 2010 - US Watson Pharmaceuticals Inc (NYSE: WPI) said yesterday that its subsidiary, Watson Laboratories Inc - Florida, filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride
Extended-release Tablets, 8 mg, 12 mg, and 16 mg.
Food and Drug Administration (FDA) of its Abbreviated New Drug Applications (ANDAs) for Hydromorphone Hydrochloride
Tablets USP, 2 mg, 4 mg and 8 mg, the generic equivalent of Purdue Pharmaceuticals' (formerly Abbott's) Dilaudid([R]) Tablets 2 mg, 4 mg and 8 mg.
completion of a non-exclusive discount agreement pursuant to A* 130a paragraph 8 sgb v to the active ingredient hydromorphone hydrochloride
(unretardiert) - atc n02aa03 for the period from 01.
Akorn also recently received regulatory approval for hydromorphone hydrochloride
injection, 10 mg/mL, in 1-mL, 5-mL and 50-mL doses.